Healio Rheuminations Podcast Por Adam J. Brown MD arte de portada

Healio Rheuminations

Healio Rheuminations

De: Adam J. Brown MD
Escúchala gratis

Rheumatology is an incredibly fast-moving and exciting field of medicine that can be difficult to keep up with. This Healio podcast provides busy clinicians with quick updates in the field of autoimmunity, with emphasis on new medications, treatment guidelines and explorations into the pathophysiology of diseases. The show will also feature historical perspectives in the field of rheumatology, as well as fascinating case presentations of medical mysteries complete with discussions from experts in the field. Ciencia Ciencias Biológicas Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Don’t forget the toes: Managing patients with ANCA vasculitis

    Don’t forget the toes: Managing patients with ANCA vasculitis
    Sep 29 2025

    Active or not active, that is the question. In this week's episode we interview Alexandra Villa-Forte, MD, MPH, a staff physician in the Center for Vasculitis Care and Research at Cleveland Clinic and a leading vasculitis expert, on a pragmatic approach to recognizing disease activity in patients with ANCA vasculitis.

    • · Intro 0:01
    • · Welcome Alexandra Villa-Forte, MD, MPH 0:10
    • · Dr. Brown sketches a potential patient that may be seen in practice 0:40
    • · How are you monitoring patients’ kidneys? 1:28
    • · How reliable are ‘no casts’ results in urinalysis tests? 4:15
    • · What is happening in the glomeruli? 5:23
    • · The importance of monitoring the urinalysis of patients with ANCA vasculitis 7:06
    • · Symptoms to watch for when tapering off medications 7:43
    • · Different scenarios with lung symptoms 9:35
    • · Evaluating patients with GPA; looking at the nose, ear and sinuses 12:20
    • · Neurologic symptoms in ANCA vasculitis 14:24
    • · Laboratory monitoring 15:52
    • · Should ANCA titers be a part of routine vasculitis monitoring? 17:05
    • · What is your approach using PJP prophylaxis in ANCA-associated vasculitis? 18:05
    • Thank you, Dr. Villa-Forte! 20:25

    We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

    Disclosures: Brown reports no relevant financial disclosures. Healio was unable to confirm relevant financial disclosures for Villa-Forte at the time of publication.
    Más Menos
    21 m
  • Healio Community Book Club: A conversation between Leonard Calabrese, DO and Eric Topol, MD, author of Super Agers

    Healio Community Book Club: A conversation between Leonard Calabrese, DO and Eric Topol, MD, author of Super Agers
    Sep 19 2025

    This special edition episode features the latest installment of Healio Community’s book club. Physician author Eric Topol, MD, discusses his book, Super Agers: An Evidence-Based Approach to Longevity, a guide to the science of living a long life free of debilitating diseases with Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology.

    · Intro by Adam J. Brown, MD 0:01

    · A warm welcome by Leonard H. Calabrese, DO 0:47

    · Introducing Eric Topol, MD 1:12

    · “Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again” but did you think it would happen this fast? 1:54

    · Let’s get into “Super Agers” 3:46

    · What’s killing most people? 6:33

    · An evidence-based treatise on healthy aging 9:42

    · The role of immune health in longevity 12:55

    · What’s next on the horizon? 16:14

    · A candle in the dark 19:40

    · Minimizing the risk of getting old while you age 22:14

    · The influence of health behaviors on immunologic wellness 25:15

    · The hot issues: GLP-1’s 26:28

    · A new world for immunology 31:50

    · Thank you, Dr. Topol 33:09

    · Thanks for listening 33:57

    Don’t miss out! To engage in future conversations like this with physician authors on Healio Community, register here.

    We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

    Disclosures: No products or companies that would require financial disclosure are mentioned in this episode.
    Más Menos
    34 m
  • The Astounding Account of the IL-17 and Spondylarthritis

    The Astounding Account of the IL-17 and Spondylarthritis
    Jul 28 2025
    In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA · Intro 0:01 · In this episode 0:12 · Leonard Calabrese, DO, is listening! 0:54 · Recap of last episode 3:09 · Putting the pieces together 5:12 · Quick overview of this science heavy episode 6:11 · What is psoriasis? 7:26 · Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:10 · In the modern world of 1986 – olive oil placebo trial 11:36 · A quick aside into fungi 12:35 · What kind of T-cells are involved here? 16:41 · The TH-1 hypothesis 18:20 · IL-23 and IL-17 are doing something 19:34 · Going back to the drawing board in 2004 20:00 · p40 + p19 = IL-23 21:00 · IL-23 via minicircle DNA in mice 23:05 · Brand new and shiny TH-17 25:23 · The family of IL-17 26:36 · What do we know about IL-17 and psoriasis? 27:10 · IL-17A vs IL-17F in mouse studies 27:35 · Finding the difference between IL-17A and IL-17F in humans 28:23 · What exactly is IL-17 doing? 29:30 · The articular manifestations of psoriatic arthritis 30:57 · Spondylarthritis and the IL 23/17 axis 33:56 · T-cells we haven’t talked about 35:40 · Summary of this episode 39:08 · Thanks for listening 41:34 We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta Bjerke R J. Acta Derm Venereol. 1982;PMID:6179355 Cargill M, et al. Am J Hum Genet. 2007;doi:10.1086/511051 Chan J R, et al. J Exp Med. 2006;doi:10.1084/jem.20060244 Cuthbert R J, et al. Ann Rheum Dis. 2019;doi:10.1136/annrheumdis-2019-215210 Ellis C N, et al. JAMA. 1986;doi:10.1001/jama.1986​ Ettehadi P, et al. Clin Exp Immunol. 1994;doi:10.1111/j.1365-2249.1994.tb06244.x Furue M, et al. Int J Mol Sci. 2020;doi:10.3390/ijms21041275 Gooderham M J, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868 Lee E, et al. J Exp Med. 2004;doi:10.1084/jem.20030451 Leonardi C L, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60725-4 Mease P J, et al. Lancet. 2000;doi:10.1016/S0140-6736(00)02530-7 Menon B, et al. Arthritis Rheumatol. 2014;doi:10.1002/art.38376 Moos S, et al. J Invest Dermatol. 2019;doi:10.1016/j.jid.2019.01.006 Muelle W, et al. N Engl J Med. 1979;doi:10.1056/NEJM197909063011016 Papp K A, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60726-6 Reinhardt A, et al. Arthritis Rheumatol. 2016;doi:10.1002/art.39732 Sherlock J P, et al. Nat Med. 2012;doi:10.1038/nm.2817 Tribe H T. Mycologist. 1998;doi:10.1016/S0269-915X(98)80100-6 Yawalkar N, et al. J Invest Dermatol. 1998;doi:10.1046/j.1523-1747.1998.00446.x Zaba L C, et al. J Allergy Clin Immunol. 2009;doi:10.1016/j.jaci.2009.08.046 Disclosures: Brown reports no relevant financial disclosures.
    Más Menos
    42 m
Todavía no hay opiniones